Table 2.

Characteristics of eligible studies

Author	Publication Year	Country	Study Design	Mean Age year	Sample Size intervention	Sample Size control	Duration of intervention (Weeks)	Dose of intervention (mg/day)	Type of control	Mean BMI
Foroozanfard et al.	2017	Iran	Single arm clinical trial	25.3	30	-	8	1500	-	26.1
Tomova et al.	2011	Bulgaria	Single arm clinical trial	26.59	13	-	24	2550	-	30.73
Sauerbrun-Cutler et al.	2012	USA	Single arm clinical trial	31.5	16	-	12	1500	-	NR
Nascimento et al.	2013	Brazil	Single arm clinical trial	26.3	16	-	8	1500	-	29.1
Panidis et al.	2010	Greece	Single arm clinical trial	21.07	15	-	24	1700	-	21.56
Neagu et al.	2012	Romania	Single arm clinical trial	NR	11	-	8	2550	-	NR
Romualdi et al.	2011	Italy	Single arm clinical trial	24.4	28	-	24	1700	-	33.59
Piltonen et al.	2005	Finland	Single arm clinical trial	30.6	26	-	24	1500	-	30.1
Dursun et al.	2015	Turkey	Single arm clinical trial	15.2	20	-	24	2000	-	30.6
Fleming et al.	2005	USA	Single arm clinical trial	30.2	82	-	32	1500/2550	-	37.1
Falbo et al.	2010	Italy	Single arm clinical trial	27.4	10	-	48	1700	-	23
Wiweko et al.	2017	Indonesia	Randomized clinical trial (parallel)	28.25	20	18	48	1500	100 mg DLBS3233 DLBS3233 is a herbal medicine produced in Indonesia	28.02
Tagliaferri et al.	2017	Italy	Randomized clinical trial (crossover)	25.62	34	34	24	1700	Placebo	32.55
Chhabra et al.	2018	India	Randomized clinical trial (parallel)	28.81	35	35	24	1700	Placebo	NR
Madsen et al.	2015	Denmark	Randomized clinical trial (crossover)	31.5	45	42	12	1700	Placebo	33.7
Fabregues et al.	2010	Spain	Randomized clinical trial (parallel)	32.06	15	15	24	1700	Placebo	25.6

BMI: body mass index; N/R: not reported